

**PSORIASIS SPECIALTY CARE PROGRAM**

Phone: **844-MILLRX-0** • Fax: **844-468-7606**

**1 PATIENT INFORMATION:**

Name: \_\_\_\_\_  
Address: \_\_\_\_\_  
City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
Phone: \_\_\_\_\_ Alt. Phone: \_\_\_\_\_  
Email: \_\_\_\_\_  
DOB: \_\_\_\_\_ Gender:  M  F Caregiver: \_\_\_\_\_  
Height: \_\_\_\_\_ Weight: \_\_\_\_\_ Allergies: \_\_\_\_\_

**2 PRESCRIBER INFORMATION:**

Name: \_\_\_\_\_  
Address: \_\_\_\_\_  
City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
Phone: \_\_\_\_\_ Fax: \_\_\_\_\_  
NPI: \_\_\_\_\_ DEA: \_\_\_\_\_  
Tax I.D.: \_\_\_\_\_  
Office Contact: \_\_\_\_\_ Phone: \_\_\_\_\_

**3 STATEMENT OF MEDICAL NECESSITY:** (Please Attach All Medical Documentation)

Date of Diagnosis: \_\_\_\_\_ Patient also taking Methotrexate?  Yes  No  
ICD-10: \_\_\_\_\_ Other: \_\_\_\_\_ Serious or active infection present?  Yes  No  
TB Test:  Positive  Negative Date: \_\_\_\_\_ Hep B ruled out or treatment started?  Yes  No  
LFT: ALT: \_\_\_\_\_ AST: \_\_\_\_\_ Date: \_\_\_\_\_ Does patient have latex allergy?  Yes  No  
Assessment:  Moderate  Mod to Severe  Severe  
% BSA affected \_\_\_\_\_  
 Scalp  Face  Chest  Arms  Hands  Nails  
 Back  Groin  Buttocks  Legs  Other: \_\_\_\_\_

**Prior Failed Treatments:**

Topicals \_\_\_\_\_  
 Methotrexate \_\_\_\_\_  
 Oral Meds \_\_\_\_\_  
 Biologics \_\_\_\_\_  
 UVA  UVB \_\_\_\_\_  
 Others \_\_\_\_\_

**If Prior Authorization is denied, recommended formulary alternatives will be provided to the prescriber based upon the patient's insurance coverage.**

**4 INJECTION TRAINING:**  To Be Administered by Pharmacist  Pharmacist to Provide Training  Patient Trained in MD Office  Manufacturer Nurse Support

**5 PICK UP OR DELIVERY:**  Delivery to Patient's Home  Delivery to Physician's Office  Pharmacy to Coordinate

**6 INSURANCE INFORMATION:** Please Include Front and Back Copies of Pharmacy and Medical Card

**PRESCRIPTION INFORMATION:** (Please be sure to choose both induction and maintenance dose where applicable)

Patient Name: \_\_\_\_\_ Patient's Date of Birth: \_\_\_\_\_

Medication	Dosage & Strength	Direction	QTY	Refills
<input type="checkbox"/> <b>CIMZIA®</b>	<input type="checkbox"/> 200mg/ml Prefilled Syringe <input type="checkbox"/> 200mg Lyophilized Powder Vial	<input type="checkbox"/> Inject 400mg SC every other week <input type="checkbox"/> <b>Induction Dose:</b> (Weight <90kg) Inject 400mg SC initially and at weeks 2 and 4 <input type="checkbox"/> <b>Maintenance Dose:</b> (Weight <90kg) Inject 200mg SC every other week		
<input type="checkbox"/> <b>COSENTYX®</b>	<input type="checkbox"/> 150mg/ml Sensoready® Pen <input type="checkbox"/> 150mg/ml Prefilled Syringe <input type="checkbox"/> 150mg/ml Lyophilized Powder Vial	<input type="checkbox"/> <b>Induction Dose:</b> Inject 150mg SC at weeks 0, 1, 2, 3, and 4 <input type="checkbox"/> <b>Induction Dose:</b> Inject 300mg SC at weeks 0, 1, 2, 3, and 4 <input type="checkbox"/> <b>Maintenance Dose:</b> Inject 150mg SC every four weeks <input type="checkbox"/> <b>Maintenance Dose:</b> Inject 300mg SC every four weeks	5 10 1 2	0 0 0 0
<input type="checkbox"/> <b>ENBREL®</b>	<input type="checkbox"/> 50mg/ml Sureclick Autoinjector <input type="checkbox"/> 50mg/ml Enbrel Mini™ Prefilled Cartridge For Enbrel Mini™ only: AutoTouch™ Autoinjector <input type="checkbox"/> 50mg/ml Prefilled Syringe <input type="checkbox"/> 25mg Lyophilized Powder Multiple Dose Vial <input type="checkbox"/> Other: _____	<input type="checkbox"/> <b>Induction Dose:</b> Inject 50mg SC twice a week (3-4 days apart) for 3 months, then start maintenance dosing <input type="checkbox"/> <b>Maintenance:</b> Inject 50mg SC once a week <b>Pediatric Patients:</b> To achieve pediatric doses other than 50mg or 25mg, use reconstituted Enbrel lyophilized powder <input type="checkbox"/> > 138lbs or more: Inject 50mg weekly <input type="checkbox"/> < 138lbs: Inject 0.8mg/kg weekly <input type="checkbox"/> Other: _____	8 4 1 4	2 0 0 0
<input type="checkbox"/> <b>HUMIRA®</b>	<input type="checkbox"/> Psoriasis Starter Package <input type="checkbox"/> 80mg/0.8ml Pen <input type="checkbox"/> 40mg/0.4ml Pen <input type="checkbox"/> 40mg/0.4ml Prefilled Syringe <input type="checkbox"/> 40mg/0.8ml Pen <input type="checkbox"/> 40mg/0.8ml Prefilled Syringe <input type="checkbox"/> Hidradenitis Suppurativa Starter Package <input type="checkbox"/> 80mg/0.8ml Pen <input type="checkbox"/> 80mg/0.8ml Prefilled Syringe <input type="checkbox"/> 40mg/0.4ml Pen <input type="checkbox"/> 40mg/0.4ml Prefilled Syringe <input type="checkbox"/> 40mg/0.8ml Pen <input type="checkbox"/> 40mg/0.8ml Prefilled Syringe <i>All strengths and dosages listed are Humira® Citrate Free</i>	<input type="checkbox"/> <b>Induction Dose:</b> Inject 80mg SC on day 1, then 40mg SC on day 8, then 40mg SC every other week <input type="checkbox"/> <b>Maintenance:</b> Inject 40mg SC every other week <input type="checkbox"/> Other: _____ <input type="checkbox"/> <b>Induction Dose:</b> <input type="checkbox"/> Inject two 80mg pens SC on day 1, then one 80mg pen SC on day 15 <input type="checkbox"/> Inject one 80mg pen SC on day 1, one 80mg pen on day 2, then one 80mg pen on day 15 <input type="checkbox"/> <b>Maintenance:</b> Inject 40mg SC on day 29 and every week thereafter <input type="checkbox"/> Patient has signed HUMIRA Complete form	3 2 3 4	0 0 0 0
<input type="checkbox"/> <b>ORENCIA®</b>	<input type="checkbox"/> 125mg/ml ClickJect™ Autoinjector <input type="checkbox"/> 125mg/ml Prefilled Syringe	<input type="checkbox"/> Inject 125mg SC once a week	4	
<input type="checkbox"/> <b>OTEZLA®</b>	<input type="checkbox"/> Starter Pack (Titration) <input type="checkbox"/> 30mg Tablets	<input type="checkbox"/> <b>Starter Pack:</b> Take one tablet in the morning on day 1, then take one tablet in the morning and one tablet in the evening as directed on the starter pack <input type="checkbox"/> <b>Maintenance:</b> Take one 30mg tablet by mouth twice daily	1 60	0 0
<input type="checkbox"/> <b>RASUVO®</b>	<input type="checkbox"/> _____	<input type="checkbox"/> _____		
<input type="checkbox"/> <b>SIMPONI®</b> (for PsA)	<input type="checkbox"/> 50mg/0.5ml Smartject Injector <input type="checkbox"/> 50mg/0.5ml Prefilled Syringe	<input type="checkbox"/> Inject 50mg SC once a month	1	
<input type="checkbox"/> <b>STELARA®</b>	<input type="checkbox"/> 45mg/ml Single-Dose Vial <input type="checkbox"/> 45mg/0.5ml Prefilled Syringe (for < 220 lbs) <input type="checkbox"/> 90mg/1ml Prefilled Syringe (for > 220 lbs) <input type="checkbox"/> Yes or <input type="checkbox"/> No: <b>STELARA SELF-INJECTION:</b> Healthcare provider certifies that patient has been trained and is eligible for self-injection	<input type="checkbox"/> <b>Induction Dose:</b> To achieve pediatric dose: <input type="checkbox"/> < 60kg: Inject 0.75mg/kg <input type="checkbox"/> 60kg - 100kg: Inject 45mg SC <input type="checkbox"/> > 100kg: Inject 90mg SC <input type="checkbox"/> Inject the contents of 1 prefilled syringe SC on day 1 <input type="checkbox"/> <b>Maintenance:</b> Inject the contents of 1 prefilled syringe SC on day 29 and every 12 weeks thereafter	1 1 1	0 0 0
<input type="checkbox"/> <b>TREMFYA™</b>	<input type="checkbox"/> 100mg/ml Prefilled Syringe	<input type="checkbox"/> <b>Induction Dose:</b> Inject 100mg/ml SC at weeks 0 and 4 <input type="checkbox"/> <b>Maintenance:</b> Inject 100mg/ml SC every 8 weeks thereafter	2 1	0 0
<input type="checkbox"/> <b>XELJANZ®</b>	<input type="checkbox"/> 5mg Tablet	<input type="checkbox"/> Take one tablet by mouth twice daily in combination with a nonbiologic DMARD	60	
<input type="checkbox"/> <b>XELJANZ® XR</b>	<input type="checkbox"/> 11mg Tablet	<input type="checkbox"/> Take one tablet by mouth once daily in combination with a nonbiologic DMARD	30	

**PRESCRIBER SIGNATURE:** I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs.

Signature: \_\_\_\_\_ Date: \_\_\_\_\_ Signature: \_\_\_\_\_ Date: \_\_\_\_\_

**Substitution Permitted**

**Dispense As Written**

Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among other things. Participation in this program is not a guarantee of prior authorization or of payment.

**Confidentiality Notice:** This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.

v11.15\_011619 © 2019 KloudScript, Inc. - All rights reserved.